## Drug Summary
Simvastatin, marketed under various brand names such as Zocor, Lipex, and many others, is a synthetic lipid-lowering medication. It belongs to the statin class, primarily used for managing abnormal lipid levels and lowering the risk of cardiovascular diseases (CVD) including heart attacks and strokes. The drug works by inhibiting the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which plays a crucial role in the production of cholesterol in the liver. This inhibition leads to lowered levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood while increasing high-density lipoprotein (HDL) cholesterol. Simvastatin has a notable effect in reducing CVD morbidity and mortality, proving beneficial even in patients with moderate risk. It has a high first-pass metabolism in the liver which results in minimal systemic exposure after oral administration.

## Drug Targets, Enzymes, Transporters, and Carriers
Simvastatin primarily targets HMG-CoA reductase, integral in cholesterol biosynthesis, and shows effects on other sectors like integrin alpha-L (ITGAL) and histone deacetylase 2 (HDAC2), potentially explaining its anti-inflammatory and plaque-stabilizing properties. Metabolism of simvastatin involves several cytochrome P450 enzymes including CYP3A4, CYP3A5, and to a lesser extent CYP2C8 and CYP2C9. Key transporters involved in its hepatic uptake include SLCO1B1 among others from the solute carrier organic anion transporter family which affect the drug's pharmacokinetics and are subject to genetic variability impacting drug response and toxicity. No specific carriers are implicated in its mechanism.

## Pharmacogenetics
Simvastatin pharmacogenetics reveals critical interactions based on genetic makeup that can influence both the efficacy and safety of the drug. Variants in **SLCO1B1**, particularly the rs4149056 polymorphism, significantly increase the risk of simvastatin-induced myopathy, a serious muscle injury. This necessitates lower dosages or alternative treatments for carriers of this risk allele. The **KIF6** gene variant, rs20455, affects cardiovascular outcomes, where carriers of certain alleles may experience greater cardiovascular benefits from high-dose simvastatin treatment. Conversely, variants in the **HMGCR** gene, like rs17244841, are associated with less pronounced reductions in LDL cholesterol, suggesting a personalized approach to dosing and choice of lipid-lowering strategy might be beneficial. These genetic associations are pivotal for tailoring statin therapy to optimize efficacy and minimize adverse effects.